Literature DB >> 22616101

Perspective: Testing failures.

Thomas Mandrup-Poulsen1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22616101     DOI: 10.1038/485s17a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Authors:  Nicole Sherry; William Hagopian; Johnny Ludvigsson; Sunil M Jain; Jack Wahlen; Robert J Ferry; Bruce Bode; Stephen Aronoff; Christopher Holland; David Carlin; Karen L King; Ronald L Wilder; Stanley Pillemer; Ezio Bonvini; Syd Johnson; Kathryn E Stein; Scott Koenig; Kevan C Herold; Anastasia G Daifotis
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

2.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

3.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Heidi Krause-Steinrauf; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Paula F McGee; Antoinette M Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane Wherrett; Darrell M Wilson; John M Lachin; Jay S Skyler
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

4.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

5.  Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Jan A Ehses; Marc Y Donath; Thomas Mandrup-Poulsen
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

  5 in total
  1 in total

1.  Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies.

Authors:  Gang Zhao; Gitanjali Dharmadhikari; Kathrin Maedler; Michael Meyer-Hermann
Journal:  PLoS Comput Biol       Date:  2014-08-28       Impact factor: 4.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.